Every week, our model comes up with 40 stocks, 20 positive and 20 negatives, to watch for next week’s trading. The model is based on a mix of fundamental and quantitative factors, built on my proprietary database of detailed earnings model on more than 1350 U.S. listed companies. The historical data for these earnings models is sourced from SEC filings. Performance of last week’s model portfolio for the week was, Net: 4.5% Longs: 11.0% Shorts: -6.5% Assuming 5% is dedicated to each position, resulting in 0% net exposure and no…
Read MoreTag: Healthcare
Stocks On My Screen For Week Starting February 1st, 2021
Every week, our model comes up with 40 stocks, 20 positive and 20 negatives, to watch for next week’s trading. The model is based on a mix of fundamental and quantitative factors, built on my proprietary database of detailed earnings model on more than 1350 U.S. listed companies. The historical data for these earnings models is sourced from SEC filings. Performance of last week’s model portfolio for the week was, Net: 2.8% Longs: -0.1% Shorts: 2.9% Assuming 5% is dedicated to each position, resulting in 0% net exposure and no…
Read MoreStocks On My Screen For Week Starting December 28th, 2020
Every week, our model comes up with 40 stocks, 20 positive and 20 negatives, to watch for next week’s trading. The model is based on a mix of fundamental and quantitative factors, built on my proprietary database of detailed earnings model on more than 1325 U.S. listed companies. The historical data for these earnings models is sourced from SEC filings. Performance of last week’s model portfolio for the week was, Net: -1.1% Longs: 0.1% Shorts: -1.2% Assuming 5% is dedicated to each position, resulting in 0% net exposure and no…
Read MoreR1 RCM Is A Rare Health Tech Winner
R1 RCM Inc. (NASDAQ: RCM), a provider of ‘revenue cycle management’ services, i.e. services ranging from patient registration to bill collection, to healthcare providers, is one of the beneficiaries of healthcare providers outsourcing front-end services. Usually, the healthcare industry, in general, is one of the slowest adopters of technology and outsourcing services, which is one of reasons space doesn’t either grow or command the trading multiple like high-growth tech niches, e.g. Cloud, but RCM seems to be making the right moves in terms of both revenue growth and profitability, shrugging…
Read MoreFulgent Genetics Is Shining Brightly Again
As we have mentioned many times before, our circle of competence is limited in the healthcare industry and that’s why we have very few healthcare names in our database, but Fulgent Genetics (Nasdaq: FLGT) is there and it is shining brightly (no pun intended). To overcome our shortcomings, we analyzed Fulgent Genetics like any other business rather than a medical test company, i.e. the company is good if it sells more, reduces the cost to manufacture, and repeats the process faster than its competitors. On those simple metrics, we are…
Read MoreBesides Wirecard’s Collapse, Paysign Has Other Positive Catalysts Too
Paysign Inc. (Nasdaq: PAYS) is an integrated prepaid card and payment processor that has multiple positive catalysts working work for it, though the stock, trading near levels seen early last year, has yet to respond to any of them. Multiple catalysts are shaping up that may lead to value unlocking opportunities for public shareholders. Problems at Wirecard AG (WDI.DE), with siphoned off cash and fraud allegations against former CEO, will not only help Paysign garner share from the troubled company’s clients but also improve the broader market dynamics, including pricing.…
Read More